Skip to main content

MPT Facts

Psychedelic; Substituted tryptamine; Serotonin 2A receptor agonist

Description

MPT (N-methyl-N-propyltryptamine) is a synthetic psychedelic of the tryptamine class. It is presumed to activate serotonin receptors in the brain, though no binding data have been published.[1]

Subjective effects include none on record — no experience report documents any psychoactive response at any dose or by any route. If an active dose exists, MPT's structural position between DMT and DPT suggests effects somewhere between the two, but this is entirely speculative.

No physical dependence data exist, and the toxic dose is entirely unknown.safety citation needed At doses high enough to overwhelm the enzyme that breaks MPT down in the gut, exposure could spike sharply and without warning.[2]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 50 mgLightnot recordedCommonnot recordedStrongnot recordedHeavynot recorded

No duration recorded for this route.

Body and dependence

Acute toxicity
Low
Chronic toxicity
Low
Physical dependence
None
Psychological dependence
Negligible
Withdrawal
None recorded
Compulsive redosing
Negligible

Tolerance

Builds
Rapid
Fully resets after
7 days
Carries over to
LSD; psilocybin; mescaline; DMT; DPT; MiPT

Effectslikely at a common dose

Perception
Color alteration; Color enhancement; Ganzfeld effect; Geometry; Visual drifting; +27 possible, including Visual haze / noise, Spatial disorientation, Vestibular distortion
Body
Pupil dilation; +26 possible, including Nausea, Dizziness, Heart rate perception changes
Thinking
none likely · 34 possible, including Cognitive impairment, Decision impairment, Confusion
Feeling
none likely · 9 possible, including Emotional lability, Anxiety, Paranoia
Self
none likely · 10 possible, including Derealization, Depersonalization, Communication suppression
Time
Time alteration; +3 possible, including Temporal disorientation

Who shouldn't take it

Absolute
Personal or family history of psychotic disorders; Concurrent MAOI use
Relative
Cardiovascular disease; Bipolar disorder; Concurrent lithium use; Concurrent SSRI/SNRI therapy

Combinations61 recorded

Lethal (1)
MAOIs
Dangerous (19)
MDMA, MDA; Alpha-2 adrenergic receptor antagonist; Dopamine agonists; DXM; GHB, Baclofen; GHB, GBL; Ibogaine; Ketamine, DXM, PCP; Lithium; Local anesthetics; MDMA, Amphetamines; NDRIs (Wellbutrin); NRIs; Psychedelics; Salvia, Ibogaine; SNRIs; SSRIs; Stimulants; Synthetic cannabinoids
Caution (37)
See full page: psychedex.org/substances/mpt
Not graded (4)
Not listed never means safe.

Seek help immediately if

Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:

  • Very high body temperature; hot, dry skin
  • Seizures
  • Chest pain; fast or irregular heartbeat
  • Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
  • Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
  • Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm

What to do

  1. Stay calm and reassure — remind them they took a drug and the effect will pass
  2. Move to a calm, quiet, safe space with low light; reduce noise and sensory input
  3. Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
  4. Talk them down gently; don't grab or restrain unless they're in danger
  5. For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
  6. If overheating, cool the body; be ready to give rescue breaths / CPR

The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1.a1 · Not medical advice

References

  1. [1]
    ^Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, et al. (2023) Pharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERT — Journal of Pharmacology and Experimental Therapeutics doi:10.1124/jpet.122.001454
  2. [2]
    ^Shen HW, Jiang XL, Yu AM (2011) Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice — Drug Metabolism and Disposition doi:10.1124/dmd.111.039107
Print version
Report an issue